CEACAM5 and neoplasm: This is in stark contrast to blood tumor markers CEA, CA15-3, and CA19-9 or liquid biopsy approach based on cfDNA/ctDNA such as Galleri by GRAIL (16.8% at stage I) (Figure 2) [21,70].